KYTX vs. RGNX, CRGX, CGEM, MESO, RLAY, IMTX, BCRX, HLVX, CABA, and PROK
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Cullinan Oncology (CGEM), Mesoblast (MESO), Relay Therapeutics (RLAY), Immatics (IMTX), BioCryst Pharmaceuticals (BCRX), HilleVax (HLVX), Cabaletta Bio (CABA), and ProKidney (PROK). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
In the previous week, Kyverna Therapeutics had 1 more articles in the media than REGENXBIO. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.13 beat Kyverna Therapeutics' score of -0.10 indicating that REGENXBIO is being referred to more favorably in the news media.
Kyverna Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 185.00%. REGENXBIO has a consensus price target of $38.45, indicating a potential upside of 133.06%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kyverna Therapeutics is more favorable than REGENXBIO.
REGENXBIO received 418 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Kyverna Therapeutics an outperform vote while only 65.89% of users gave REGENXBIO an outperform vote.
Kyverna Therapeutics has higher earnings, but lower revenue than REGENXBIO.
18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Kyverna Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -291.99%. Kyverna Therapeutics' return on equity of 0.00% beat REGENXBIO's return on equity.
Summary
Kyverna Therapeutics beats REGENXBIO on 9 of the 15 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
